Now we have three kinds of powered sheaths, the Excimer laser, Evolution, and TightRail. All three devices are suggested to have almost equal safety and efficacy. At the present time, operators can select the device depending on their preferences, experience, and the cost-effectiveness. However, to further evaluate and optimize the lead extraction techniques and tools, more randomized prospective multicenter trials are required.
Use of a powered sheath for transvenous lead extraction
Over the past 40 years, the population of patients with cardiac implantable electronic devices (CIEDs) has increased. Consequently, the number of patients requiring transvenous lead extraction (TLE) procedures has been increasing. Implanted leads develop fibrotic adhesions that bind the leads to adjacent structures. To overcome this issue, several tools have been invented in clinical medicine.
In the 1990s, the Excimer laser sheath (Spectranetics, Colorado Springs, CO, USA) was introduced as the first powered sheath. A randomized trial of TLEs using the Excimer laser sheath and conventional extraction sheath (PLEXES trial) was performed. The rate of achievement of the complete lead removal was 94% in the laser group and 64% in the conventional sheath group (P = .001). This study suggested the significant clinical advantages of a laser sheath.
Successively, the LExICon study, which was a multicenter study to examine the safety and efficacy of a laser sheath-assisted TLE, was published in 2010. In this study, TLEs were performed in 1,449 patients (2,405 leads). The median implantation duration was 82.1 months. The leads were completely removed 96.5% of the time, with a 97.7% clinical success rate. The major adverse events occurred in 20 patients were directly related to the procedure (1.4%) including four deaths (0.28%). This study elucidated that TLE employing laser sheaths was highly successful with a low procedural complication rate. Moreover, the registries performed in Europe, the USA, and Canada have reported a complete procedural success rate of 90%, partial lead removal of 3%-4%, major perioperative complications rate of 2%, and in-hospital mortality of <1%. The Excimer laser system is highly effective in TLE procedures; however, it has some disadvantages. First, the Excimer laser system is highly expensive because a double investment into the laser sheath itself and an Excimer laser system are required. Second, the ablative effects of the Excimer laser on calcified lesions are minimal. This suggests that normally functioning, non-recalled leads can be extracted in selected patients. Therefore, the number of TLEs is expected to increase year by year.
